In the last trading session, 1.0 million shares of the Aquestive Therapeutics Inc (NASDAQ:AQST) were traded, and its beta was 2.05. Most recently the company’s share price was $2.52, and it changed around $0.05 or 2.02% from the last close, which brings the market valuation of the company to $249.15M. AQST currently trades at a discount to its 52-week high of $5.80, offering almost -130.16% off that amount. The share price’s 52-week low was $2.20, which indicates that the current value has risen by an impressive 12.7% since then. We note from Aquestive Therapeutics Inc’s average daily trading volume that its 10-day average is 1.49 million shares, with the 3-month average coming to 1.61 million.
Aquestive Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.11. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 0 recommended AQST as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Aquestive Therapeutics Inc is expected to report earnings per share of -0.16 for the current quarter.
Aquestive Therapeutics Inc (NASDAQ:AQST) trade information
Instantly AQST has showed a green trend with a performance of 2.02% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.69 on recent trading dayincreased the stock’s daily price by 6.32%. The company’s shares are currently down -29.21% year-to-date, but still down -3.82% over the last five days. On the other hand, Aquestive Therapeutics Inc (NASDAQ:AQST) is -11.27% down in the 30-day period. We can see from the shorts that 10.02 million shares have been sold at a short interest cover period of 7.49 day(s).
The consensus price target as assigned by Wall Street analysts is $8.5, which translates to bulls needing to increase their stock price by 70.35% from its current value. Analyst projections state that AQST is forecast to be at a low of $7 and a high of $10.
Aquestive Therapeutics Inc (AQST) estimates and forecasts
The year-over-year growth rate is expected to be -13.87%, down from the previous year.
Consensus estimates provided by 8 financial analysts predict the company will bring in an average of 12.23M in revenue for the current quarter. 8 analysts expect Aquestive Therapeutics Inc to make 12.17M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 12.05M and 20.1M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 1.47%. Forecasts for the next quarter put sales growth at -39.45%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 27.90%. Aquestive Therapeutics Inc earnings are expected to increase by -30.07% in 2025, but the outlook is positive 13.68% per year for the next five years.
AQST Dividends
Aquestive Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Mar-04.
Aquestive Therapeutics Inc (NASDAQ:AQST)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 5.04% of Aquestive Therapeutics Inc shares, and 48.37% of them are in the hands of institutional investors. The stock currently has a share float of 50.94%. Aquestive Therapeutics Inc stock is held by 153.0 institutions, with BRATTON CAPITAL MANAGEMENT, L.P. being the largest institutional investor. By 2024-06-30, it held 10.7918% of the shares, which is about 9.81 million shares worth $25.51 million.
VR ADVISER, LLC, with 6.1109% or 5.56 million shares worth $14.44 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 2.4 shares worth $6.06 million, making up 2.43% of all outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held roughly 1.92 shares worth around $4.83 million, which represents about 1.94% of the total shares outstanding.
